ANI PHARMACEUTICALS, INC Notes Payable, Fair Value Disclosure
ANI PHARMACEUTICALS, INC (ANIP) had Notes Payable, Fair Value Disclosure of $131.40 million as of 2015-09-30, per its 10-Q filed 2015-11-03.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:NotesPayableFairValueDisclosure · last filed 2015-11-03
- 2015-09-30: Notes Payable, Fair Value Disclosure $131.40M.
- 2015-06-30: Notes Payable, Fair Value Disclosure $163.70M.
- 2015-03-31: Notes Payable, Fair Value Disclosure $165.90M.
| Period end | Notes Payable, Fair Value Disclosure |
|---|---|
| 2015-09-30 | $131.40M 10-Q · filed 2015-11-03 |
| 2015-06-30 | $163.70M 10-Q · filed 2015-08-04 |
| 2015-03-31 | $165.90M 10-Q · filed 2015-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |